2,3,4'-Trihydroxy-4-methoxybenzophenone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4'-Trihydroxy-4-methoxybenzophenone
• 英文别名: (2,3-dihydroxy-4-methoxyphenyl)-(4-hydroxyphenyl)methanone
• 化学式: C₁₄H₁₂O₅
• 分子量: 260.24
• InChiKey: YYQLEVUVEAKBKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Methods for treating congenital disorders of glycosylation
  申请人：Maggie's Pearl, LLC

  公开号：US11160794B2

  公开（公告）日：2021-11-02

  The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.

  本公开一般涉及用于增加糖基化和治疗先天性糖基化紊乱的化合物和药物组合物。
• Methods and compositions for treating metabolic disorders
  申请人：Mootha Vamsi Krishna

  公开号：US20090143279A1

  公开（公告）日：2009-06-04

  The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.
• Method of Treating Transplant Rejection and Autoimmune Diseases
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20140050694A1

  公开（公告）日：2014-02-20

  A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of SU-5416 is disclosed.
• METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION
  申请人：Perlara PBC

  公开号：US20210030721A1

  公开（公告）日：2021-02-04

  The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.
• [EN] BENZOPHENONE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZOPHÉNONE
  申请人：UNIV SHEFFIELD

  公开号：WO2009081141A1

  公开（公告）日：2009-07-02

  The invention relates to a series of benzophenone compounds of formula (I): wherein R1 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and in particular, but not exclusively to the use of said compounds in the treatment of motor neurone disease or a disease where oxidative stress may be a contributory factor.